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African trypanosomiasis is a disease caused by infection of humans and animals with various species or subspe-
cies of trypanosomes, usually through the bite of infected tsetse lies, although some have adapted to other means 
of transmission and are no longer bound geographically to the tsetse habitat1. Unfortunately, most of the current 
drugs are inefective due to drug resistance and eforts towards new drug development are inadequate1,2. Large 
numbers of synthetic chemo-types have been produced and tested on protozoan pathogens, yet have mostly 
failed to deliver new treatments for parasitic diseases. A particular problem remains with drugs against parasites 
causing the ‘most neglected tropical diseases’. hus, most of the current drugs are old, and parasitic strains have 
become resistant to these drugs3–5. Unfortunately, the development of new and eicient anti-protozoan drugs has 
not received much attention or funding from the pharmaceutical industry for the reason that most of these dis-
eases occur in resource-poor communities where the people sufering from these diseases cannot aford to pay the 
high price of the drugs, but rely heavily on subsidized or donated drugs6. Consequently, investing in drug devel-
opment against especially tropical parasitic diseases is economically unattractive. he search for anti-parasitic 
drugs from natural sources, especially from secondary metabolites derived from plants, is a good alternative to 
synthetic drugs, considering that medicinal plants have been used for centuries for treating infectious diseases7–9.
Natural products continue to play a signiicant role in the development of new chemotherapies. For instance, 
in the years 1981 to 2006, 1,184 new drugs were developed and registered for use, out of which 28% were of nat-
ural origin. Another 24% of all the new drugs registered within this period had functional groups with pharma-
cological activity (pharmacophores) derived from natural products10. Although there have been many promising 
developments to identify leads against tropical protozoan parasites using various plant extracts, the translation 
of these results into actual drug candidates has not occurred. In most cases the active principles of these plant 
extracts remain unknown due to a lack of research facilities and funding. Moreover, the speciic mechanism of 
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action of these reported bioactive extracts or bioactive principles is rarely, if ever, determined (e.g., triptolide; 
curcumin)11. However, a comprehensive understanding of the interaction of a drug lead with its molecular target 
is especially helpful for the process of drug development, for the reason that it allows the use of medicinal chem-
istry approaches for optimization, and in some cases a more suitable clinical trial design. his is crucial for the 
development of new and eicient chemotherapy that will replace the current ineicient drugs. Here we report on 
a detailed investigation of the mode of action of a clerodane (16-α-hyroxy-cleroda-3,13 (14)-Z-dien-15,16-olide, 
HDK-20; Fig. 1) previously isolated from Polyalthia longifolia12 on Trypanosoma brucei trypomastigotes.
Results
ơơ ? ?T. b. brucei 
Ǥ he efect of HDK20 on trypanosome proliferation was studied 
ater both continuous and a limited-duration exposure. he result shows that the growth pattern of cells with long 
time exposure were very similar to those with a short exposure to the compounds (Fig. 2). At a concentration of 
0.4 µg/mL, corresponding to 1 × EC50, the efect was to slow growth, particularly ater 12 h; ater 24 h the growth 
rate had slowed to almost zero, but microscopical observation revealed little evidence of cell death as the cells 
were intact and normally motile; the cell density became signiicantly diferent from their untreated controls at 
24 h and beyond (P < 0.01; unpaired t-test). At 2 × EC50, the trypanostatic efect occurred earlier (P < 0.05 at 8 
and 12 h for continuous and pulsed exposure, respectively), and the cell population started dying ater 24 h; no 
live cells were detected ater 28 and 32 h in the continuous and 1-h pulse exposure groups, respectively. In the 
4 × EC50 group (1.6 µg/mL), the cell population was sterilized ater 12 h, regardless whether the cells were exposed 
for 1 h or continuously to the compound (signiicantly diferent from control at 4 h (P < 0.01) and 8 h (P < 0.05) 
for continuous and pulsed exposure, respectively). hese results show unambiguously that the efects of HDK20 
on trypanosomes are irreversible ater a limited exposure time of 1 h.
Figure 1. Structure of 16α-hydroxycleroda-3,13 (14)-Z-dien-15,16-olide, HDK20, showing in vitro activity 
against trypomastigotes of T. brucei as previously reported12.
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 ? ?Ǥ he 
efects of varying concentrations of the test compound on membrane permeabilization were monitored over a 
6-hour period using the luorescent probe propidium iodide. his compound is excluded from trypanosomes 
unless there is a loss in plasma membrane integrity, usually brought on by a drug treatment, which allows entry, 
upon which the probe binds nucleic acids and emits a strong luorescence signal13. Digitonin, which rapidly per-
meabilizes the cells, was used a positive control and indicates the level of luorescence where all cells have become 
permeable to propidium iodide (PI).
Figure 3 shows that the compound led to a partial loss of plasma membrane integrity, which would start 
to afect cellular viability during the 6 hours of incubation, at concentrations of 2× and 4× their EC50 values. 
Trypanosomes treated with 0.8 µg/mL (2 × EC50) of HDK20 started becoming appreciably luorescent ater 
approximately 2–3 hours of incubation, but afecting only some 25% of cells during the 6-h period; however, 
when this concentration was doubled (1.6 µg/mL), the cells became luorescent as early as 1–2 hours ater the 
start of the incubation and the signal continued to increase to >50% by 6 h, indicating a steady increase in the 
number of cells with plasma membranes that had become permeable to PI. None of the treated groups reached 
the maximum luorescence within the duration of the experiment as indicated by the digitonin-treated control 
cells. All this was consistent with the growth curves depicted in Fig. 2. Yet, the growth curve showed clear efects 
on population growth rates, with trypanostatic efects at 1–2 × EC50 that are not easily explained in terms of the 
disintegration of the plasma membrane, and we conclude that the cell membrane permeabilization visualized in 
Fig. 3 as PI luorescence is the result of cell death, rather than that being the cause of cell death.
Figure 2. Growth curve of T. brucei grown in the continuous presence of HDK20 at indicated concentrations, 
or untreated (no drug) (solid symbols and lines), or ater exposure to the same concentrations for 1 h only (open 
symbols, dashed lines). Seeding density was 2 × 105 cells/mL, incubations were at 37 °C and 5% CO2. Values 
obtained were plotted against time using GraphPad Prism 5 sotware. he experiment was conducted over 48 h; 
no live cells could be detected microscopically in cultures with 4 × EC50 at the 24 h time point, and at the 36 h 
point in cultures treated with 2 × EC50. he data are the average and SEM of three independent experiments, 
each performed in triplicate; where no error bars are shown, they fall within the symbol. here were no 
signiicant diferences between continuous and pulse data points for any of the concentrations tested (P > 0.05; 
unpaired Student’s t-test).
Figure 3. Results showing the speed of action of HDK20 on trypanosomes. Digitonin, a compound known to 
cause rapid cell permeabilization was used as positive control. Separate traces (background luorescence were 
recorded in the absence of cells and these were subtracted from those presented herein. a = digitonin treated 
cells; b = 4 × EC50; c = 2 × EC50; d = cells + PI (untreated); e = media + PI (no cells).
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 ? ?Ǥ Some compounds puriied from natural sources elicit 
their activity by inhibiting progression of the cell cycle, for instance by binding to a protein required for cell divi-
sion, or by intercalating with DNA. hus, an understanding of cell cycle events may help in deciphering the mode 
of action for HDK20, especially given the efects on in vitro growth at 1–2 × EC50, and we assessed the efect of 
low, non-lethal concentrations of this test compound on cell cycle progression in trypanosomes.
Examination of DNA coniguration by luorescence microscopy with the DNA stain DAPI revealed progres-
sive cell cycle defects from 8 hours of incubation with just 0.2 µg/mL HDK20 (0.5 × EC50). Under these condi-
tions, kinetoplast division could not be completed or perhaps not initiated, leading to a dramatic increase in the 
percentage of cells in G1/S phase, with one nucleus (1 N) and one kinetoplast (1 K), and a concomitant decrease 
in cells in all stages of the cell division process (Fig. 4), leading to the nearly complete disappearance of dividing 
cells from the treated populations, while the proportions of 1N1K and 2N2K cells remained constant in the 
non-treated population grown in parallel. his result showed that the (initiation of) DNA synthesis, particularly 
of kinetoplast DNA (kDNA), might be a target for the trypanocidal activity of the test compound. he apparent 
G1 or S-phase cell cycle arrests induced by the continuous exposure to low concentrations of the compound for 
up to 30 h are consistent with the growth inhibition depicted in Fig. 2.
      T. brucei    ? ?Ǥ 
Fluorescence microscopy ater DAPI staining showed that 70% of the cell population incubated with HDK-20 
(0.4 µg/ml) contained one nucleus and one kinetoplast (1N1K) DNA ater 8 hours of incubation (Supplementary 
Figure S1), consistent with the observation, made above, that HDK20 causes cell cycle arrest of T. brucei in G1 
phase. Although the mitochondrion and kinetoplast of the cells remained apparently normal throughout the 
experiment, in some cells treated with HDK20 the nucleus appeared to have fragmented, with multiple nuclear 
fragments but only 1 kinetoplast (Supplementary Figure S1); this was not observed in the untreated control cells, 
throughout the period of the experiment.
Ǥ Cell cycle defects may lead to apoptosis or pro-
grammed cell death, and the latter is known to be linked with DNA fragmentation. Conversely, cell cycle arrest 
may be the result of DNA damage. Consequently, a TUNEL assay was used to study DNA fragmentation upon 
incubation with 0.4 µg/mL HDK20. Br-dU luorescence was strongly increased in cells ater 12 hours incuba-
tion with HDK20 (P < 0.01), slightly higher than the positive control, cells treated with the antibiotic phleomy-
cin, which is known to cause double-strand breaks14 including in T. brucei15,16 (P < 0.05) (Fig. 5, Supplementary 
Figure S2).
ơǦ ? ?T. b. brucei treated cells. HDK20 
afected the cell cycle progression of T. brucei cells in this study, leading to an apparent accumulation of cells 
in the G1 phase of the cell cycle and the accumulation of 1N1K cells. A direct causal efect has been previously 
reported between the mitochondria membrane potential and cell cycle progression in T. brucei17. Consequently, 
we examined whether this compound afects the mitochondrial function in bloodstream trypanosomes and 
whether this occurs before or ater the cell cycle defects observed earlier.
Figure 6 presents a summary of the mitochondrial potential (∆Ψm) changes during 12 h of incubation with 
or without the test compound and read at 0, 1, 4, 8 and 12 h. As expected, there was no change in the ∆Ψm 
for untreated cells for the duration of the experiment (12 h), whereas valinomycin induced a very rapid and 
strong depolarisation of the ∆Ψm ater just 1 h of incubation, and troglitazone caused a clear hyperpolarisation 
of the mitochondrial membrane. HDK-20, even at a relatively low concentration (0.4 µg/mL) induced a rapid 
Figure 4. Cell cycle determination in T. b. s427 WT using DAPI. Fixed cells prepared on slides were viewed 
under a luorescence microscope ater up to 32 h of incubation with 0.2 µg/mL HDK20 (open symbols, dashed 
lines); the untreated control culture (no drug; closed symbols, solid lines) was grown in parallel. Values were 
expressed as percentage of 500 counted cells. N = nucleus; K = kinetoplast; e = early stage; L = late stage with 
initiated cytokinesis. Sample micrographs of each cell division stage are provided in Supplementary Figure S1.
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and profound depolarisation of the parasites’ mitochondrial membrane potential at the irst time point (1 h of 
incubation) and the trend continued until a near complete depolarization was achieved ater 12 hours. he low 
cytometry histograms are provided as Supplementary Figure S3. his result indicates that HDK20 induced a rapid 
depolarisation of mitochondrial membrane potential as an early efect on the parasites.
ơ ? ?T. b. brucei. he ∆Ψm experiment revealed that HDK20 caused 
depolarisation of the mitochondrial membrane of T. brucei, which in bloodstream forms is maintained by the 
oligomycin-sensitive FoF1 ATP synthase
18. One possibility is that a reduction in cellular ATP levels leads to the 
reduced mitochondrial membrane potential by interfering with ATP production (or the mitochondrial ADP/
ATP exchanger), thereby denying the F1Fo-ATPase the ATP it needs to pump H
+ across the inner mitochondrial 
membrane. In that scenario, one would expect to see a dramatic reduction in cellular ATP levels preceding the 
Figure 5. DNA fragmentation of treated and untreated T. brucei s427 cells following 12 hours of incubation with 
the test compound (HDK20, 0.4 µg/mL) or without the test compound (untreated cells), and with phleomycin 
(2 µg/ml; positive control. his result is a summary of the histogram plots presented in Supplementary Figure S2. 
*p < 0.05; **p < 0.01 (n = 3). A.U., arbitrary units of luorescence.
Figure 6. Mitochondrial membrane potential (∆Ψm) of treated and untreated T. b. brucei bloodstream forms. 
∆Ψm was determined with a low cytometer using T. b. brucei (bloodstream-form) incubated with 25 nM 
tetra-methylrhodamine (TMRE), and expressed as the percentage of cells exhibiting >200 A.U. Troglitazone 
(10 µM) was used as mitochondrial membrane hyperpolarization control, while valinomycin (100 nM) was used 
as mitochondrial membrane depolarization control. A shit to a higher luorescence indicates hyperpolarisation 
(increased ∆Ψm); while a shit to a lower luorescence is indicative of a decreased ∆Ψm (depolarization) (See 
Figure S3).
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rapid decline in ∆Ψm. In order to assess this possibility, we tested the efect of HDK20 on ATP production, at the 
same concentration and over the same period as assessed on ∆Ψm.
Intracellular ATP levels of T. brucei treated with HDK20 were found to be severely depleted, but only ater 
several hours of incubation (Fig. 7). Although the intracellular ATP level in the cells treated with HDK20 trended 
down ater just one hour of incubation, this only became statistically signiicant ater 2 hours of incubation with 
the test compound. Oligomycin was used as a positive control as it speciically inhibits the T. brucei F1Fo-ATPase, 
which in bloodstream forms pumps protons out across the inner mitochondrial membrane18; oligomycin is 
known to reduce ATP levels in bloodstream trypanosomes by 50%17,19, and if HDK20 likewise acts directly on this 
ATPase it should mirror the actions of this inhibitor. he fact that oligomycin induced a much more rapid deple-
tion of ATP, compared to that exhibited by HDK20 (at a concentration that rapidly depolarised the mitochondrial 
membrane (Fig. 6)), seems to indicate that this test compound does not, in fact, directly inhibit the F1Fo-ATPase. 
Moreover, the gradual decline in ATP content clearly shows that HDK20 irst depolarises the inner mitochondrial 
membrane, which subsequently impacts on ATP production.
Discussion
We have previously reported the promising activity of HDK20 against T. brucei12 and here report an investiga-
tion of the cellular and biochemical efects this natural compound, isolated from the Nigerian medicinal plant 
Polyalthia longifolia12, exerts on the parasites. We observed that the compound rapidly (within 1 h) and irre-
versibly induced cell cycle arrest in G1 phase, followed by cell death at concentrations below 1 µg/mL; this was 
accompanied by double strand DNA breaks. In that irst hour of incubation, the compound caused a strong depo-
larization of the mitochondrial membrane, leading to a slower decline in ATP levels as mitochondrial function 
deteriorated.
he G1 phase cell cycle arrest, leading to 100% of the cell population with 1 nucleus and 1 kinetoplast ater 
incubation with 0.2 µg/mL HDK20 (0.5 × EC50), was not simply the result of the reduction in ATP levels, which 
reached approximately 50% ater 8 h, as the dividing cells appeared to complete their cell cycles: there was no 
accumulation of cells in any stage of the cell division process. Instead, there was an apparent failure to initiate a 
new cell division cycle, speciically the failure to replicate the kinetoplast, as the number of 1N2K cells rapidly 
declined upon treatment with HDK20 (Fig. 4). he conclusion that already initiated cell division was completed 
seems to explain the slight increase in cell density observed in cells incubated with concentrations as high as 
0.8 µg/mL or 1.6 µg/mL HDK20 over the irst few hours (Fig. 2).
In addition, HDK20 has previously been shown to be able to inhibit recombinant Leishmania donovani 
Topoisomerase I20, which could certainly contribute to the appearance of double strand breaks, if not to the very 
rapid efect on ∆Ψm. he related compound clerocidin reportedly inhibits Topoisomerase II in cancer cells, 
leading to an accumulation of cells in G2/M phase and only 2% of cells in G1 phase ater 17 h of incubation with 
the compound21 – in sharp contrast to the near-100% accumulation in G1 phase reported here ater incubation 
of ≥24 h with HDK-20, which is not indicative of a principal action through topoisomerase inhibition. We thus 
propose that the efects on ∆Ψm are directly responsible for the cell cycle efects, which starts with the replication 
of the lagellar basal body and the kinetoplast22, and that inhibition of topoisomerases20,21 may be responsible 
for the observed DNA fragmentation in the TUNEL assay and also plays a role in a multi-target activity against 
trypanosomes.
he kinetoplast of trypanosomatids is a structure of mitochondrial DNA that is highly organised, and is made 
up of tens of maxicircles and thousands of minicircles23. To ensure that T. brucei daughter cells receive identi-
cal kDNA networks, the process of replication is highly synchronized with replication of the nuclear materials, 
prior to cell division; thus, the mitochondrial S-phase for kDNA replication is initiated before the longer nuclear 
S-phase22,24. Indeed, the initiation of mitochondrial division appears to be an essential checkpoint that must 
precede nuclear division, leading necessarily to the creation of 1N2K cells before the onset of nuclear division 
and mitosis22,25. he here observed accumulation of 1N1K cells thus appears to indicate a failure to either initiate 
Figure 7. ATP concentrations in 1 × 107 treated and untreated T. brucei cells. Incubation was for a period of 
12 hours, with samples taken at each indicated time point. he results shown here are the averages and SEM of 
four fully independent experiments.
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or complete the mitochondrial S-phase, i.e. kDNA replication. With the mitochondrial S-phase not being con-
cluded, the nuclear S-phase would not commence, resulting in the observed cell cycle arrest at 1N1K.
Replication of the kDNA is dependent on intracellular ATP and hundreds of mitochondrial proteins26, which 
are imported into the mitochondria27 by a process that is dependent on both ATP and ∆Ψm28. It is therefore rea-
sonable to conjecture that the severe depletion of ATP and the decrease of the parasites’ mitochondrial membrane 
potential interfered with the successful initiation or conclusion of kDNA replication, resulting in cell cycle arrest 
due to the failure of cells to enter (or progress from) the kinetoplast G1 phase.
In conclusion, the mode of action of HDK20 against T. brucei appears to be multi-targeted, inlicting irre-
versible cell cycle arrest on trypanosomes. Additional mode of action studies, an investigation of the Structure 
Activity Relationship (SAR) and analysis of related compound libraries could further improve the eicacy of this 
compound. Importantly, HDK20 has been reported to be non-toxic and orally active, displaying promising activ-
ity in a hamster model of visceral leishmaniasis20.

Ǥ All experiments were performed with bloodstream trypomastigotes 
of T. b. brucei strain Lister 427, grown in culture exactly as described, in Hirumi’s Modiied Iscove’s medium 9 
(HMI-9; Life Technologies) supplemented with 10% heat-inactivated Fetal Calf Serum (FCS; Biosera), 14 µL/L 
β-mercaptoethanol (Sigma), and 3.0 g/L sodium hydrogen carbonate (Sigma) per litre of medium, pH 7.4 (com-
plete HMI-9) at 37 °C in a 5% CO2 atmosphere
29.
ơơ ? ?T. b. brucei fol-
ǦǤ Varying concentrations of the test compound were tested on 
trypanosomes for determination of in vitro cell growth using cell counts. Trypanosomes at their mid logarithmic 
phase of growth were taken from cultures and the cell density, determined with a haemocytometer, was adjusted 
to 2 × 105 cells/mL with fresh complete HMI-9 medium. Ater predetermined periods of exposure to the test 
compound, cell counts were taken in triplicate, for each concentration of the compound, typically for up to 32 h. 
he experiment was repeated two more times and the counts of the three independent determinations were aver-
aged and used for plotting the growth curve. For the time-limited exposure time experiments, the initial seeding 
density was 2 × 105 cells/mL, the cells were treated with the test compound at varying concentrations except for 
the drug-free control. he cultures were irst incubated at 37 °C and 5% CO2 for a brief period of 1 hour, ater 
which the cells were washed twice with fresh media by centrifuging at 1200 RCF, re-seeded (2 × 105 cells/mL) 
in fresh HMI-9 media, and samples were taken and counted at each time point. he counting was performed in 
triplicate and the average values obtained were plotted against time using Prism 5 sotware (GraphPad).
ȋȌǤ Propidium iodide (Sigma-Aldrich) was used to 
monitor the efect of the test compound on trypanosome survival in real time30,31. Trypanosomes become luo-
rescent when the plasma membrane is breached and PI enters the cell and binds to nucleic acids13. For this assay, 
100 µL of complete HMI-9 was added to 2 wells of a 96-well plate and a further 100 µL of complete HMI-9 but 
containing 3.2 µg/ml of HDK20, was added to the irst well; 100 µL from this well (1.6 µg/ml HDK20) was then 
added to the second well to achieve a 0.8 µg/ml solution, ater which 100 µL was removed from the second well 
and discarded. A third well received 100 µl of 20 µM digitonin in HMI-9, to serve as positive control for luores-
cence when all cells rapidly lyse, and a fourth well contained HMI-9 medium only, to serve as negative control. 
To each well was added 100 µL of complete HMI-9 containing 2 × 106 trypanosomes and 18 µM of PI. A inal well 
containing the same inal concentration of PI (9 µM) in complete HMI-9 but no cells served to record background 
luorescence in the absence of cells, which was subtracted from the other traces. he plates were incubated in a 
FLUOstar OPTIMA luorimeter (BMG Labtech) at 37 °C with 5% CO2 atmosphere, and the luorescence was 
recorded at 544 nm excitation and 620 nm emission for 6 hours.
ȋ∆ΨȌƪǤ Changes 
in the mitochondrial membrane potential (∆Ψm) due to exposure of trypanosomes to the test compound 
were determined using low cytometry ater loading the cells with tetramethylrhodamine ethyl ester (TMRE; 
Sigma-Aldrich)32,33. he cell density was adjusted to 1 × 106 cells/mL with and without test compound for the 
start of the experiment. 1 mL of sample was transferred at each time point into a microfuge tube and centrifuged 
at 1200 RCF for 10 min at 4 °C. he pellet was re-suspended in 1 mL PBS containing 200 nM of TMRE, fol-
lowed by incubation at 37 °C for 30 min. he suspension was placed on ice for at least 30 min before analysis by a 
Becton Dickinson FACS Calibur using a FL2-heigth detector and CellQuest, and FlowJo sotware30. Valinomycin 
(100 nM; Sigma-aldrich) and troglitazone (10 µM; Biomol) were employed as negative (mitochondrial membrane 
depolarization) and positive (mitochondrial membrane hyperpolarization) controls respectively30,32. ∆Ψm was 
determined at 0, 1, 4, 8 and 12 h.
ƤȋȌƪ
microscopy. Cells were incubated for various times in the presence and absence of HDK20, washed twice 
in ilter-sterilized 1× PBS, spun at 2,600 rpm for 10 minutes and re-suspended in 1 mL of 1× PBS. 50 µl of the 
re-suspended cells were spread onto a glass microscope slide, and were let to air dry, the cells were then ixed in 
1 mL of 70% methanol in PBS overnight at 4 °C. he mitochondrial integrity was examined by incubating 5 × 105 
cells/mL with 100 nM Mito-Tracker Orange CMTMRos luorescent dye (hermoFisher Scientiic, UK)34. he 
coniguration of nuclei and kinetoplasts of treated and untreated T. brucei was visualized using the luorescent 
DNA dye 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, CA, USA), using a Zeiss Axioplan micro-
scope as described15. A total of 500 cells per slide were counted for each sample, and scores for DNA coniguration 
were given according to these groups: 1N1K, 1N2K, 2N2K (Early) and 2N2K (Late), where N is nuclear DNA; 
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and K is kinetoplast DNA; Early and Late refer to the absence or presence, respectively, of an ingression furrow as 
indicator of cytokinesis in the cell division process of trypanosomes.
Ǥ Fragmentation of parasite DNA ater exposure 
with the test compound was evaluated by TUNEL assay using the APO-BrdU TUNEL Assay Kit (Invitrogen) 
for the detection of DNA fragmentation caused by the effect of drug treatment, and utilizes 5-Bromo-
2′-Deoxyuridine 5′-Triphosphate (BrdUTP) and Terminal deoxynucleotidyl transferase (TdT) enzyme. his was 
carried out following the manufacturer’s protocol, and exactly as previously described16. he treated samples were 
analysed by low cytometry using both FL3- width and Anti-BrdU FITC detectors and cell Quest sotware. he 
data obtained was analysed with FlowJo 10 sotware.
	T. brucei using luciferase. Intracellular ATP was measured using an 
ATP Determination Kit (Invitrogen), which contains recombinant irely Luciferase and Luciferin, following the 
manufacturer’s protocol. Briely, cultures containing 1 × 107 cells of both treated and untreated parasites were 
taken and centrifuged for 10 min at 1200 × g (4 °C). he resulting pellets were washed twice in 200 µL of 50 mM 
Tris-HCl, pH 7.4, containing 0.1 mM Dithiothreitol (DTT). he cells were then lysed by sonication on ice (10 sec-
onds twice, separated by 30 s) using a Soniprep 150 with amplitude set at 8 µm. Ater this, it was centrifuged 
at 17,000 × g for 10 min at 4 °C. he resultant supernatant was frozen in liquid nitrogen and stored at −80 °C. 
Cellular ATP levels were measured and quantiied using a serially diluted standard (0.5 µM–500 pM) following 
the manufacturer’s protocol, measuring luminescence with a FLUOstar OPTIMA plate reader.
Ǥ All data generated or analysed during this study are included in this published article (and 
its Supplementary Information iles).
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